Newsroom

Light microscopy of red blood cells, some are infected with Plasmodium

News

It has long been known that bacterial pathogens are becoming increasingly resistant to antibiotics. However, common medications are also becoming less effective against malaria, a tropical disease caused by a parasite. To counteract this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH), has now developed a new drug candidate that can kill the malaria pathogen even when existing drugs are no longer effective. The team has now published its findings in the journal Angewandte Chemie.

22.10.2025

HIPS

Fluorescence microscopy of cells in magenta and blue

News

Natural products derived from microorganisms are a promising source of new active ingredients, but are often produced only in very small quantities. A research team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) led by Tobias Gulder has now succeeded in establishing a chemo-enzymatic platform for the production of furanolides – a class of natural products with a broad spectrum of activity. This strategy not only allows furanolides to be produced cost-effectively, but also enables structural modifications to be made. The newly generated molecules are capable of effectively combating both bacterial pathogens and cancer cells. The team has now published its findings in the Journal of the American Chemical Society.

20.10.2025

HIPS

Two speakers in front of a presentation on a screen

News

On 9 and 10 October 2025, the One Lab Retreat of the Helmholtz Centre for Infection Research (HZI) took place at the Wyndham Hannover Atrium. Researchers, managers and task force representatives from all HZI sites came together to present current scientific results, discuss interdisciplinary topics and further develop strategic cooperation.

13.10.2025

News

Professor Rolf Müller, Scientific Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biology at Saarland University, has been awarded the Mannich Medal by the German Pharmaceutical Society (DPhG). Awarded in honour of the German chemist Carl Mannich, the medal is the DPhG's highest scientific accolade and is presented annually for “outstanding achievements in the field of pharmaceutical sciences”. The medal was presented at the DPhG's annual conference in Freiburg on October 1, 2025. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

07.10.2025

HIPS

A woman puts a strip of chewing gum in her mouth

News

Influenza is much more than just a nasty cold – it is one of the most dangerous infectious diseases worldwide, claiming around half a million lives every year. What makes it particularly insidious is that flu viruses are contagious even before the first symptoms appear. Despite this threat, the diagnostic options available to date are far from ideal. They are often expensive, complicated to use and simply unavailable in many poorer regions of the world. A research team led by Professor Lorenz Meinel from the University of Würzburg in cooperation with researchers from the Helmholtz Centre for Infection Research has developed the technology behind a new self-test for influenza, recently published in ACS Central Science.

02.10.2025

HZI Campus

News

Five young scientists were honored in Innsbruck on Wednesday for their internationally outstanding work: The Life Sciences Research Awards Austria 2025 of the Austrian Society for Molecular Biosciences and Biotechnology (ÖGMBT) went to Victoria Deneke (IMP Vienna), Rémi Hocq (TU Vienna) and Eugenia Pankevich (CeMM). The Life Sciences PhD Awards Austria 2025 went to Yannick Weyer (Medical University of Innsbruck) and Max Kellner (formerly IMBA, since 2025 Helmholtz Centre for Infection Research (HZI)).

25.09.2025

HZI Campus

Back to the first page
...
3
4
5
6
...
150

HZI in the media

Dr. Rolf Müller, Managing Director of Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), were both named laureates of the

22.12.2025

Research Information

... ein Interview mit Josef Penninger geführt . Er ist wissenschaftlicher Geschäftsführer des Helmholtz-Zentrum für Infektionsforschung in ...

21.12.2025

T3N

Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für Infektionsforschung (HZI) in ...

19.12.2025

healthcare-in-europe.com

Biosyntheseweg aufzuklären. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Zusammenarbeit mit ...

18.12.2025

Bionity.COM

Finanzierungsmöglichkeiten fehlen.

Josef Penninger, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI)

16.12.2025

MedMedia

Korte from the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI).

The research was carried out as

12.12.2025

The Hindu

... des Leibniz Lungenzentrums Borstel, des Helmholtz-Instituts für Pharmazeutische Forschung Saarland sowie weiterer wissenschaftlicher ...

12.12.2025

Bionity.COM

Einrichtungen des regionalen Forschungsökosystems – darunter das Helmholtz-Zentrum für Infektionsforschung (HZI), das Deutsche Zentrum für

12.12.2025

EUROPE SAYS

Korte of the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI). The findings emerged from the

12.12.2025

The New Indian Express

Universität Würzburg. Seit 2018: Postdoc am Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), Entwicklung Bayes’scher ...

12.12.2025

BIOspektrum

Center Borstel - Leibniz Lung Center, the Helmholtz Institute for Pharmaceutical Research Saarland and other scientific institutions in

11.12.2025

Technology Networks

von Humboldt professor, head of department at the Helmholtz Centre for Infection Research, Braunschweig and full professor at the Hannover

10.12.2025

European Research Council

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.